A list of gene editing study/studies currently underway that may potentially benefit patients with Usher syndrome. Please refer to the link under each trial for more information on that trial. Please be aware, all information provided are for informational purposes only, and are in no way endorsed or approved by Usher Syndrome Ireland.
Pre-Clinical Development Stage
Editas Medicine recently made headlines around the world with their first ever in-human gene editing for a different inherited retinal disease, LCA. They are currently developing several programs, and one is EDIT-102 for Usher syndrome 2a (USH2A).
“Mutations in exon 13 of the USH2A gene are most often responsible for the development of USH2A. This information supports the design of a CRISPR medicine that edits exon 13 to restore healthy USH2A protein expression, consequently restoring the function of photoreceptors.”
More information can be found here: https://www.editasmedicine.com/gene-editing-pipeline/
Call/Text
+353 (89) 262 4696
(Mon-Fri 10am-4pm)
Address
15 Windsor Terrace,
Dun Laoghaire, Co. Dublin,
A96 RF29
Reg. Number: 688621
Reg Charity Number: 20206288
Copyright © 2021 - 2023 Usher Syndrome Ireland - All Rights Reserved.